IXICO PLC secured £1.3 million in new contracts, including an Alzheimer's biomarker validation and an extension of a Huntington's disease clinical trial. These wins bring IXICO's order book close to fully covering its £7.5 million revenue forecast for the year ending September 2026. The Alzheimer's contract supports FDA clearance for a new diagnostic test, while the Huntington's extension adds new analysis methods, highlighting strong client ties. Despite ongoing losses due to investments, IXICO's broker forecasts 15% revenue growth this year and 20% next year, with improved margins and a strong cash position after a recent fundraise.
Verizon announced it will distribute over 2,500 free tickets for all 64 FIFA World Cup 2026 matches held in US host cities exclusively to Verizon customers on June 1, 2026. Selected winners can also receive "Golden Tickets" for premium sideline exper...
The US government is investing $2 billion in nine quantum computing companies, including Infleqtion, D-Wave Quantum, and Rigetti Computing, as part of a strategy to advance quantum technology for economic and national security benefits. IBM and Globa...
e.l.f. Beauty reported Q4 earnings of 32 cents per share, surpassing analyst estimates of 29 cents, with revenue of $449.29 million beating the expected $422.93 million. The company's growth was significantly boosted by the acquisition of Rhode, cont...
I-ON Digital Corp. reported a net income of $4.2 million for Q1 2026, driven by gains from its digital asset ecosystem and gold-backed tokenization. The company strengthened its balance sheet by reducing debt and liabilities, improving its equity pos...
Astec Industries announced that its CEO, CFO, and Senior VP of Investor Relations will participate in one-on-one meetings with investors at the KeyBanc Capital Markets Industrials and Basic Materials Conference on May 27, 2026. This event is an oppor...
